Disease Markers

Disease Markers / 2018 / Article
Special Issue

Biomarkers in Heart Failure and Associated Diseases

View this Special Issue

Review Article | Open Access

Volume 2018 |Article ID 3406028 | https://doi.org/10.1155/2018/3406028

Larisa-Diana Mocan Hognogi, Cerasela-Mihaela Goidescu, Anca-Daniela Farcaş, "Usefulness of the Adipokines as Biomarkers of Ischemic Cardiac Dysfunction", Disease Markers, vol. 2018, Article ID 3406028, 8 pages, 2018. https://doi.org/10.1155/2018/3406028

Usefulness of the Adipokines as Biomarkers of Ischemic Cardiac Dysfunction

Guest Editor: Marco Proietti
Received29 Jun 2018
Accepted13 Sep 2018
Published10 Oct 2018


Cardiovascular disease is the leading cause of death among both women and men, but there is still a great percentage of misdiagnosis and lack of clearly defined criteria. Advances in biomolecular science have proven the crucial role of inflammation and, more importantly, the role of adipokines in mediating all stages of coronary artery disease. It has also been suggested that regional fat deposits, more precisely from thoracic region, have a major influence on the development of coronary artery disease by creating a local proatherogenic environment. The immune system closely interacts with metabolic risk factors to initiate, promote, and further aggravate the atherosclerotic lesions on the arterial wall all with the “help” of adipokines. So nowadays, research extensively focuses on uncovering biomarkers that would provide an increased chance of detecting subclinical cardiac distress and also add a consistent value to current guideline-imposed risk criteria.

1. Introduction

The adipose tissue secretes several hormone-like molecules called adipokines, which participate in body physiology regulation. Adipokines, pleiotropic molecules, also play a role in diseases such as diabetes, atherosclerosis, and autoimmune diseases, among others [1]. The adipokine group includes classical cytokines (e.g., tumor necrosis factor-α (TNFα), interleukin-6 (IL-6)), specific chemokines (interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), macrophage inflammatory protein-2α (MIP-2α), stromal cell-derived factor-1 (SDF-1)), growth factors (e.g., transforming growth factor-β (TGF-β)), and proteins of the alternative complement system (e.g., adipsin, acylation-stimulating protein). The group also includes proteins involved in vascular hemostasis (e.g., plasminogen inhibitor activator-1 (PAI-1), tissue factor), lipid metabolism (leptin, retinol-binding protein, and cholesteryl ester transfer protein), glucose homeostasis (e.g., adiponectin, resistin), and angiogenesis (e.g., vascular endothelial growth factor (VEGF)), as well as acute phase and stress responses (e.g., haptoglobin, metallothionein) [2, 3]. Production of these proteins by adipose tissue is increased in obesity and has led to the idea that obese patients are characterised by a state of chronic low-grade inflammation, that links causally to insulin resistance and the metabolic syndrome. Figure 1 describes the role of obese adipocytes in the inflammation and pathogenesis of atherosclerosis [4].

There is no doubt that inflammation is viewed as an important pathophysiological step in the development of atherosclerosis. There are a multitude of studies that address this issue and also the issue of the interaction between the immune mechanisms and metabolic risk factors. This interaction initiates, promotes, and activates the lesions in the coronary arteries, and currently, efforts are made to find the key biomarkers that could unveil the risk of the progression of atherosclerosis in patients with metabolic disorders.

2. Adipokines as Biomarkers in Atherosclerotic Heart Disease

2.1. Biomarker Definition

A biomarker is a “characteristic that is objectively measured and evaluated as an indicator of the normal biological process, pathogenic processes, or pharmacologic responses to a therapeutic intervention” [5]. An ideal biomarker should be used for screening, prognostic, and diagnostic purposes (Figure 2).

Recent research has shown that medicine needs precision, and it is important to have in mind that people are different with respect to genes, environment, and lifestyle factors and that treatments need to be more effective and targeted. This is one of the reasons that we need prognostic, pharmacodynamic, or predictive biomarkers [6, 7].

When introducing a new biomarker, one has to keep in mind that this novel molecule needs to be as close as possible to an “ideal biomarker” regarding accuracy and standardization of determination, reproducibility, accessibility, high sensibility, and specificity and it should also make an impact in the clinical care of a patient [8].

When interpreting the serum levels of a biomarker, one should refer to the following: (i)Reference limits: these are cut-off values statistically established taking into consideration disease-free individuals(ii)Discriminative limits: these are the limits that impose a decision. For example, if we take into account troponin, the 99 percentile is discriminative for acute myocardial infarction so that we can correctly assess patients with acute myocardial infarction apart from healthy individuals(iii)Risk limit: this is the limit from where we consider a greater risk

At the present time, there are only a few number of established biomarkers (e.g., NT-proBNP, BNP, cTnI, cTnT, CRP, and D-dimers) but important research is being conducted in developing new ones as the diagnostic, prognostic, and therapeutic impact is remarkable.

2.2. Classification of Biomarkers in Cardiovascular Disease

There is a large number of biomarkers evaluated or under evaluation in relation with cardiovascular disease, and detailing all of them exceeds the purpose of this paper. But, if we strictly refer to atherosclerotic disease, they can be grouped as follows [6, 10]: (i)Biomarkers for acute changes: copeptin, high sensitivity troponin, galectin-3, ST-2, heart fatty acid-binding protein (H-FABP), pregnancy-associated plasma protein-A (PAPP-A), ischemia-modified albumin (IMA)(ii)Biomarkers for chronic changes: coronary calcium(iii)Biomarkers of inflammation: C-reactive protein, interleukin-6, fibrinogen, monocyte chemotactic protein-1, TNF-alpha, myeloperoxidase, soluble fragment CD40 ligand (sCD40L), angiotensin II, E-selectin, heat shock proteins, matrix metalloproteinases (MMP), myeloperoxidase (MPO), platelet endothelial cell adhesion molecule-1 (PECAM-1), intracellular cell adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1)(iv)Biomarkers of metabolic disorders: lipoprotein (a), low-density lipoproteins, high-density lipoproteins, apoB100, lipoprotein-associated phospholipase A2, homocysteine, adiponectin, haptoglobin, visfatin, leptin, resistin, etc.

Some of the above listed are already documented as biomarkers, so the present paper refers to those that derive from the adipose tissue and that are still under research but with promising results, which we have also confirmed in our studies.

2.2.1. Visfatin in Atherosclerosis

Visfatin is a new identified adipokine that plays a role as a proinflammatory mediator in the process of atherosclerosis and also in plaque destabilization, also known as NAMPT (nicotinamide phosphoribosyltransferase) and PBEF (pre-beta cell-enhancing factor). Research has shown that this adipokine has insulin mimetic features and is involved in the process of pancreatic pre-beta cell maturation. It was first described in 2005 by Fukuhara and his collaborators [11]. These authors showed that visfatin correlates with visceral fat. Even though their research paper was partially retracted due to technical issues, mainly, the multiple functions of this cytokine were confirmed in an increasing number of studies. Also, it was demonstrated that bariatric surgery in morbidly obese patients helped lower the plasma level of visfatin 6 months afterwards [12]. Obesity and T2DM are independent risk factors for atherosclerotic disease, and it seems that plasma levels of visfatin are increased in this set of subjects. Kadoglou et al. demonstrated this in 2010, in a study conducted on 120 diabetic patients without clinical vascular complications, compared with age- and sex-matched healthy individuals [13].

Visfatin acts on a large number of sites as follows [14]: (i)Endothelial wall: angiogenesis, tumor growth, cardiac fibrosis(ii)Cardiomyocytes(iii)Vascular tone: in healthy subjects, it promotes vasodilation, but in subjects with T2DM, it promotes vasoconstriction(iv)Extracellular matrix: it determines augmentation in MMP2/9 release which promotes plaque weakening

As it is well known by now, arterial hypertension, dyslipidemia, smoking, and T2DM determine repetitive lesions on the endothelium of the arterial vessels. This leads to a growing inflammatory response. There are a number of authors that have demonstrated that in the presence of inflammation, visfatin levels are increased. Visfatin may contribute to cardiac fibrosis indirectly via the vascular endothelium and acts at this level (of the endothelium) by superactivating ERK-NT-kB-iNOS axis, thus activating among others, matrix metalloproteinases. Visfatin also enhances the production of myocardial repair tissue (when cardiomyocytes were acutely exposed to it) and remodeling (if cardiomyocytes were chronically exposed to it) via upstreaming matrix metalloproteinase-9 and vascular endothelial growth factor [15]. This is confirmed by demonstrating the superexpression of mRNA. Also, eNAMPT enhances cardiac hypertrophy via calcineurin/NFAT signaling pathway—a genetic mechanism involved in cardiac hypertrophy. Visfatin is also known as NAMPT (nicotinamide phosphoribosyltransferase), and NAMPT has the role as an NAD+-synthesizing enzyme within the cell (iNAMPT). This enzyme protects against cardiac hypertrophy by maintaining optimal high levels of NAD+. But when released into the circulation, eNAMPT acts as a proinflammatory adipokine, cytokine, and growth factor and induces endothelial dysfunction and destabilization of atherosclerotic plaque [16].

Therefore, in concern to the involvement of visfatin in the atherosclerotic plaque, this is due to the fact that it acts like an intracellular regulator of NAD+-dependent reactions in the muscle cell. It also promotes vascular inflammation and proliferation in association with atherosclerotic plaque [17].

Until now, the majority of research showed that visfatin might be in relation with obesity but mostly in the presence of T2DM. Hypertension does not seem to alter visfatin plasma levels. Our study, conducted on two different types of hypertensive patients, also confirms these findings [18].

If we were to analyze visfatin, from a biomarker view, one notices that, at this moment, it seems to meet some of the criteria mentioned before: (i)it has high specificity: values to be found elevated in T2DM with obesity(ii)it adds value on traditional risk: patients with obesity and T2DM who also had high visfatin plasma levels seem to have more advanced atherosclerosis

With respect to the response to therapy, it was found that lipid-lowering therapy significantly lowers visfatin plasma levels. Also, there are a number of studies that show that inhibiting visfatin might represent a novel therapeutic approach in cardiovascular or cerebrovascular complications of atherosclerosis [19].

2.2.2. Apelin in Atherosclerosis

Apelin is a relatively newly discovered peptide, with various and significant activities within the human body. Initially, it was considered to be an adipocytokine, but it was concluded that its most important actions are directed to the cardiovascular system particularly in the endothelium and myocardium. Both apelin and its receptor, APJ, are highly expressed in the vessels and heart. It is synthetized as preprohormone and then cleaved in fragments of different lengths [2023]. The majority of its effects are chain links in a complicated and intricate protection mechanism which is designed to regulate basic functions of the organism, aid the regenerative processes, and slow the diseases. It is subject for research in various fields and pathologies, the researchers’ attention being focused on apelin-13, the most important apelin isoform for the cardiovascular system [24]. Its protective activity is mainly accomplished through antagonism of the renin-angiotensin-aldosterone system, but other mechanisms are revealed in the latest research [2528].

This protective effect of apelin is expressed also on the atherosclerotic process and its development [29, 30]. Apelin-13 inhibits the formation of the macrophage foam cells; the main mechanism for that is the activation of the protein kinase C and initiation of some molecular pathways that in the end will significantly reduce the cholesterol level in the macrophage foam cells and the production of foam cells themselves [31]. In this process, the stimulation of autophagy is the key effect [32]. In favor of this result came the observations of Cui et al. about microRNAs; their increased expression has an interesting effect of reducing the expression of apelin in macrophages concomitant with increasing the lipid accumulation and lowering the efflux of cholesterol from macrophages. At the same time, the apelin molecules that were resistant to microRNA effects continued to inhibit the accumulation of lipids in the macrophages. According to Cui et al. observations, miRNA-497 is involved in modulating the efflux of oxidized LDL cholesterol from the THP-1 macrophages and apelin is one of the molecule from the downstream molecular chain reactions. Overexpression of miRNA-497 was observed to significantly reduce the expression of apelin in THP-1 macrophages [33]. Enforced expression of miR-497 promoted lipid accumulation and decreased cholesterol efflux in oxLDL-exposed THP-1 macrophages. In contrast, downregulation of miR-497 suppressed oxLDL-induced lipid accumulation in THP-1 macrophages. Overexpression of miR-497 significantly reduced the expression of apelin in THP-1 macrophages. The levels of microRNA studied in this research were increased and negatively correlated with the level of apelin in the atherosclerotic lesions [34].

The experimental studies showed that the administration of apelin-13 results in lower levels of proinflammatory cytokine secretion (interleukin-6, interleukin-1β, and tumor necrosis factor-α) and lower expression of lipoprotein lipase, and so, it favors the reduction of lipid accumulation in the vascular wall [35]. In experimental models of aortic abdominal aneurysm induced by elastase, the exogen apelin administration reduces the content of macrophages within the aortic wall and the chemokine production and in the end, reduces the formation of aortic aneurysm [36].

The initial studies showed that in patients with acute coronary syndromes, the level of apelin lowered as the severity of coronary stenosis increased. Highly unstable atherosclerotic plaques were associated with lower levels of apelin [37, 38]. Furthermore, this peptide appears to be involved in the development of collateral vessels in patients with stable angina; the study of Akboga et al. showed that apelin can be a predictor of collateral vessel development, besides other factors such as the severity of stenosis or the presence of right coronary occlusion or severe multivessel disease. In their research, apelin was an independent predictor of good coronary collateral network.

Although the data is still incomplete, apelin appears to be an atheroprotective factor, and most important, it shows potential for therapeutic manipulation but also for risk stratification. But further studies are needed to clarify both the predictive value of this marker and its therapeutic value.

Atherosclerosis is a major pathology which affects all vital organs and is a cause for severe morbidity and mortality, with increased costs. Any therapeutic modulation of the pathophysiologic process in order to limit the clinical consequences is welcomed, and apelin appears to be an important potential target for treatment. Another potential target could be the adipose tissue macrophage activation as suggested by the paper of Boutens et al. [39].

2.2.3. Leptin in Atherosclerosis

Through the adipocytokines released by the fatty tissue, after a unique metabolic rewiring, the fat tissue influences the inflammation in the whole body, particularly the atherosclerotic lesion development [40]. Leptin is an adipocytokine produced in the adipose tissue with a primary role of regulating the food intake and energetic metabolism, in order to keep the fat tissue at a constant level. It is an anorectic agent through actions on the hypothalamus; because obese patients have a high level of serum leptin, it was thought that the main mechanism in obesity is a resistance to leptin [41].

This adipocytokine has also an important activity on the cardiovascular system. It was shown that it is both atherogenic and antiatherogenic factors, and it appeared to be a predictive marker for cardiovascular events. Its importance as a protective factor is not yet clarified, although it was suggested that hyperleptinemia might not be directly linked to atherogenesis, but it might reflect and be a consequence of a state of leptin resistance. The obesity paradox was described, and it represents only a small part of the complex molecular system that controls and promotes the inflammation and its effect on blood vessels [4244].

It appears that high levels of leptin promote the production of other inflammatory mediators such as tumor necrosis factor, interleukin-2, and interleukin-6 and increase the production of the reactive oxygen radicals. Leptin stimulates the proliferation and hypertrophy of smooth muscle cells within the vessel wall and the accumulation of cholesterol esters in foam cells, particularly if associated with hyperglycemia [42, 45]. It is well known that all these effects contribute to endothelial dysfunction and promote the development and progression of atherosclerotic lesions, but it is not yet clear if leptin itself can induce the atherosclerotic process or it is only a marker of the biological context in which the vascular lesions are produced.

Leptin was intensely studied in cardiovascular patients, and it was observed that it is predictive for metabolic syndrome, myocardial infarction and coronary events in men and hypertensive women, and ischemic stroke [42, 46]. In combination with adiponectin, another adipocytokine with protective effects for the vessels, leptin is a valuable marker for the prediction of the atherosclerotic process, both their serum values being useful, but more importantly their ratio (leptin/adiponectin) [47].

Leptin, together with adiponectin, is a link in the adipovascular axis, connecting the excessive fat tissue with inflammation and atherosclerosis, and all the pathologies that derive from their imbalance. The leptin/adiponectin ratio is a new and better marker for atherosclerosis (and for monitoring the atherosclerotic index), insulin resistance, and endothelial dysfunction, but gender differences must be kept in mind because of the hormonal influences on the adipose metabolism and adipokine production [47].

2.2.4. Resistin in Atherosclerosis

Human resistin, a 12.5 kDa cysteine-rich polypeptide [48] circulating in different molecular isoforms [49], is expressed at lower levels in adipocytes but at higher levels in circulating monocytes and macrophages [50] and vascular endothelium [51]. It has proinflammatory effects by nuclear factor-kappa B (NF-κB) activation and production of cytokines (IL-6, IL-1, TNF-alpha, and monocyte chemoattractant proteins) [52, 53]. At the same time, it exerts vascular remodeling effects by the stimulation of angiogenesis [54], proliferation capacity [55], and expression of endothelin-1, VCAM-1, and MCP-1 [56] by vascular smooth muscle cells. Resistin also decreases the production of nitric oxide in coronary endothelial cells and increases the production of reactive oxygen species (ROS) [57].

As a result, resistin stimulates monocytes, endothelial cells, and vascular smooth muscle cells, thereby inducing atherosclerosis in experimental animals [58]. These experimental evidences, together with clinical studies demonstrating the association of resistin plasma levels with obesity [59, 60], metabolic syndrome (MetS) [61], and ischemic heart disease [62, 63], suggest that resistin might play a role in the interaction between insulin resistance, inflammation, and atherosclerosis [59, 60]. Several studies have shown that variants of the resistin gene and their imbalance have an impact on metabolic parameters and cardiovascular risk [64, 65]. Subjects with 420C/G allele showed increases in resistin plasma concentrations [66, 67], elevated glucose levels at birth [68], high HbA1c levels [69], and increased risk of T2DM [65]. At the same time, they also had increased levels of triglycerides and higher prevalence of MetS and obesity [61]. In both females and males, the G allele of the 420C/G of the resistin gene polymorphism appears to be associated [70] with higher risk for cardiovascular events [61], cerebrovascular disease, and stroke [69, 71]: more severe stroke and higher in-hospital mortality in patients with acute ischemic stroke [72]. Similarly, subjects with allele 299A (allele +299 (G>A) alleles) exhibited high glucose levels at birth, and in diabetic patients, the resistin levels correlated with cerebrovascular disease especially in males [72].

Although these characteristics make resistin a good biomarker of atherosclerosis, its relationship with IMT—a marker of initial asymptomatic atherosclerosis—has been reported only in obese children [73] but there is no evidence of this association in obese adults [74]. In contrast, in obese patients, resistin correlated with key components that correlate vascular risk parameters to the development of atherosclerosis: platelet number and volumes (MPV), serum and platelet P-selectin, fibrinogen, PAI-1 ag (plasminogen activator inhibitor-1 antigen), and PMPs (platelet-derived microparticles [16, 46, 74]). At the same time, increased resistin levels found in smokers correlate with insulin resistance, while both in smokers and nonsmokers, they are not related to C-reactive protein, homocysteine, and uric acid levels [12, 46, 70].

In addition, patients with premature coronary atheromatosis (diagnosed on coronary angiogram or with acute infarction before 45 years) showed elevated serum levels of resistin compared to those without, in the presence of the same risk factors (even in the absence of significant differences between risk factors) [75]. Moreover, in a cohort of patients, resistin has been shown to be an independent predictor of acute coronary syndromes (ACS) (in patients without a history of myocardial infarction or stroke) and for cardiac or cerebrovascular events (in patients with coronary artery disease [63]). Patients with unstable angina and acute myocardial infarction (STEMI or NSTEMI) have elevated serum levels of resistin, suggesting a possible role as a diagnostic biomarker for acute coronary events [76, 77]. Resistin levels increase starting at 3–6 hours after the onset of chest pain and peaked at 12 hours. In an average follow-up of 83.4 months, resistin levels were an independent predictor of a new acute ACS [78, 79] in patients with coronary artery disease [80]. In patients with stable angina treated by PCI, resistin levels increased at 12 hours after the procedure but did not correlate with the increases in troponins levels [81].

The relationship of resistin with the risk of stroke requires a further study. One study on postmenopausal women found an association between increased resistin levels and the risk of stroke, regardless of the presence of obesity and other risk factors for cardiovascular disease [82], a conclusion not confirmed by another large study [83]. Serum resistin levels were able to predict mortality at 5 years and functional outcomes in patients with ischemic stroke [84, 85]. Studies have also identified resistin levels in patients with overt peripheral atherosclerosis. In one study, these were elevated in patients with peripheral arterial disease (PAD) compared to those with ischemic heart disease [86] and plasma levels of resistin and diastolic BP were predictors of new ischemic events and readmission for nonfatal myocardial infarction, heart failure, or critical limb ischemia in these patients. Moreover, in patients with PAD who underwent bypass surgery, increased levels of resistin were able to predict the reduced free survival range without amputation in patients with critical limb ischemia, regardless of the presence of diabetes [87].

3. Conclusion

Nowadays, we are facing a tremendous amount of information that puts us, as practitioners, in front of many decisions that have to be as accurate as possible. Research in the last decades proved that obesity is extremely bound to systemic inflammation and that visceral adiposity increases cardiovascular risk, namely, the risk of cerebrovascular disease and myocardial infarction. Chronic inflammation is linked to endothelial dysfunction and elevated prothrombin activity, and therefore, there is still a need to evaluate the impact of the adipokines in relation to various clinical outcomes of atherosclerosis so that these molecules could become great tools to predict the dynamics and therapeutic response of the disease.

Conflicts of Interest

There is no conflict of interest to be declared.


  1. V. Andrade-Oliveira, N. O. S. Câmara, and P. M. Moraes-Vieira, “Adipokines as drug targets in diabetes and underlying disturbances,” Journal of Diabetes Research, vol. 2015, Article ID 681612, 11 pages, 2015. View at: Publisher Site | Google Scholar
  2. P. Trayhurn and J. H. Beattie, “Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ,” The Proceedings of the Nutrition Society, vol. 60, no. 3, pp. 329–339, 2001. View at: Publisher Site | Google Scholar
  3. P. Trayhurn and I. S. Wood, “Adipokines: inflammation and the pleiotropic role of white adipose tissue,” British Journal of Nutrition, vol. 92, no. 3, pp. 347–355, 2004. View at: Publisher Site | Google Scholar
  4. R. Opatrilova, M. Caprnda, P. Kubatka et al., “Adipokines in neurovascular diseases,” Biomedicine & Pharmacotherapy, vol. 98, pp. 424–432, 2018. View at: Publisher Site | Google Scholar
  5. Biomarkers Definitions Working Group, “Biomarkers and surrogate endpoints: preferred definitions and conceptual framework,” Clinical Pharmacology & Therapeutics, vol. 69, no. 3, pp. 89–95, 2001. View at: Publisher Site | Google Scholar
  6. R. Dhingra and R. S. Vasan, “Biomarkers in cardiovascular disease: statistical assessment and section on key novel heart failure biomarkers,” Trends in Cardiovascular Medicine, vol. 27, no. 2, pp. 123–133, 2017. View at: Publisher Site | Google Scholar
  7. F. S. Collins and H. Varmus, “A new initiative on precision medicine,” The New England Journal of Medicine, vol. 372, no. 9, pp. 793–795, 2015. View at: Publisher Site | Google Scholar
  8. L. Vida-Simiti, Angina Pectorala Instabila, Casa Cartii de Stiinta, Cluj Napoca, 2003.
  9. G. Zhao, C. A. Okoro, S. S. Dhingra, F. Xu, and M. Zack, “Trends of lack of health insurance among US adults aged 18-64 years: findings from the Behavioral Risk Factor Surveillance System, 1993-2014,” Public Health, vol. 146, pp. 108–117, 2017. View at: Publisher Site | Google Scholar
  10. B. McDonnell, S. Hearty, P. Leonard, and R. O'Kennedy, “Cardiac biomarkers and the case for point-of-care testing,” Clinical Biochemistry, vol. 42, no. 7-8, pp. 549–561, 2009. View at: Publisher Site | Google Scholar
  11. A. Fukuhara, M. Matsuda, M. Nishizawa et al., “Visfatin: a protein secreted by visceral fat that mimics the effects of insulin,” Science, vol. 307, no. 5708, pp. 426–430, 2005. View at: Publisher Site | Google Scholar
  12. D. G. Haider, K. Schindler, G. Schaller, G. Prager, M. Wolzt, and B. Ludvik, “Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 4, pp. 1578–1581, 2006. View at: Publisher Site | Google Scholar
  13. N. P. Kadoglou, N. Sailer, A. Moumtzouoglou et al., “Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes,” Experimental and Clinical Endocrinology & Diabetes, vol. 118, no. 2, pp. 75–80, 2010. View at: Publisher Site | Google Scholar
  14. L. D. M. Hognogi and L. V. Simiti, “The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome,” Clujul Medical, vol. 89, no. 3, pp. 322–326, 2016. View at: Publisher Site | Google Scholar
  15. V. B. Pillai, N. R. Sundaresan, G. Kim et al., “Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 304, no. 3, pp. H415–H426, 2013. View at: Publisher Site | Google Scholar
  16. L.-F. Lu, C.-P. Wang, T.-H. Yu et al., “Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction,” Cytokine, vol. 57, no. 1, pp. 74–80, 2012. View at: Publisher Site | Google Scholar
  17. S. Y. Lim, S. M. Davidson, A. J. Paramanathan, C. C. T. Smith, D. M. Yellon, and D. J. Hausenloy, “The novel adipocytokine visfatin exerts direct cardioprotective effects,” Journal of Cellular and Molecular Medicine, vol. 12, no. 4, pp. 1395–1403, 2008. View at: Publisher Site | Google Scholar
  18. D. Mocan-Hognogi, R. Mocan-Hognogi, A. Maluțan, A. Farcaş, and L. Vida-Simiti, “Determining visfatin/NAMPT serum levels by ELISA technique in pregnant women with preeclampsia,” Revista de Chimie, vol. 68, no. 9, p. 3, 2017. View at: Google Scholar
  19. T. Romacho, C. F. Sanchez-Ferrer, and C. Peiro, “Visfatin/Nampt: an adipokine with cardiovascular impact,” Mediators of Inflammation, vol. 2013, Article ID 946427, 15 pages, 2013. View at: Publisher Site | Google Scholar
  20. C. M. Goidescu and L. A. Vida-Simiti, “The apelin-APJ system in the evolution of heart failure,” Clujul Medical, vol. 88, no. 1, pp. 3–8, 2015. View at: Publisher Site | Google Scholar
  21. C. M. Goidescu, F. P. Anton, D. C. Leucuța, P. A. Mircea, and L. A. Vida-Simiti, “Serum level of apelin-13 negatively correlated with NT-proBNP in heart failure patients,” Revista Romana de Medicina de Laborator, vol. 24, no. 4, pp. 399–412, 2016. View at: Publisher Site | Google Scholar
  22. W. Koguchi, N. Kobayashi, H. Takeshima, M. Ishikawa, F. Sugiyama, and T. Ishimitsu, “Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure,” Circulation Journal, vol. 76, no. 1, pp. 137–144, 2012. View at: Publisher Site | Google Scholar
  23. M. Soliman and M. Arafah, “Apelin protect against multiple organ injury following hemorrhagic shock and decrease the inflammatory response,” International Journal of Applied & Basic Medical Research, vol. 5, no. 3, pp. 195–199, 2015. View at: Publisher Site | Google Scholar
  24. E. Y. Zhen, R. E. Higgs, and J. A. Gutierrez, “Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma,” Analytical Biochemistry, vol. 442, no. 1, pp. 1–9, 2013. View at: Publisher Site | Google Scholar
  25. I. Szokodi, P. Tavi, G. Földes et al., “Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility,” Circulation Research, vol. 91, no. 5, pp. 434–440, 2002. View at: Publisher Site | Google Scholar
  26. A. G. Japp, N. L. Cruden, G. Barnes et al., “Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure,” Circulation, vol. 121, no. 16, pp. 1818–1827, 2010. View at: Publisher Site | Google Scholar
  27. K. Siddiquee, J. Hampton, D. McAnally, L. May, and L. Smith, “The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition,” British Journal of Pharmacology, vol. 168, no. 5, pp. 1104–1117, 2013. View at: Publisher Site | Google Scholar
  28. K. Siddiquee, J. Hampton, S. Khan et al., “Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production,” Journal of Hypertension, vol. 29, no. 4, pp. 724–731, 2011. View at: Publisher Site | Google Scholar
  29. S. L. Pitkin, J. J. Maguire, R. E. Kuc, and A. P. Davenport, “Modulation of the apelin/APJ system in heart failure and atherosclerosis in man,” British Journal of Pharmacology, vol. 160, no. 7, pp. 1785–1795, 2010. View at: Publisher Site | Google Scholar
  30. Y. Kang, J. Kim, J. P. Anderson et al., “Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development,” Circulation Research, vol. 113, no. 1, pp. 22–31, 2013. View at: Publisher Site | Google Scholar
  31. X. Y. Liu, Q. Lu, X. P. Ouyang et al., “Apelin-13 increases expression of ATP-binding cassette transporter A1 via activating protein kinase C α signaling in THP-1 macrophage-derived foam cells,” Atherosclerosis, vol. 226, no. 2, pp. 398–407, 2013. View at: Publisher Site | Google Scholar
  32. F. Yao, Y. C. Lv, M. Zhang et al., “Apelin-13 impedes foam cell formation by activating class III PI3K/Beclin-1-mediated autophagic pathway,” Biochemical and Biophysical Research Communications, vol. 466, no. 4, pp. 637–643, 2015. View at: Publisher Site | Google Scholar
  33. J. Cui, Z. Ren, W. Zou, and Y. Jiang, “miR-497 accelerates oxidized low-density lipoprotein-induced lipid accumulation in macrophages by repressing the expression of apelin,” Cell Biology International, vol. 41, no. 9, pp. 1012–1019, 2017. View at: Publisher Site | Google Scholar
  34. X. Zhang, Q. Ye, D. Gong et al., “Apelin-13 inhibits lipoprotein lipase expression via the APJ/PKCα/miR-361-5p signaling pathway in THP-1 macrophage-derived foam cells,” Acta Biochimica et Biophysica Sinica, vol. 49, no. 6, pp. 530–540, 2017. View at: Publisher Site | Google Scholar
  35. N. J. Leeper, M. M. Tedesco, Y. Kojima et al., “Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 296, no. 5, pp. H1329–H1335, 2009. View at: Publisher Site | Google Scholar
  36. Y. Zhou, Y. Wang, and S. Qiao, “Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients,” International Heart Journal, vol. 55, no. 3, pp. 204–212, 2014. View at: Publisher Site | Google Scholar
  37. S. Gunter, A. Solomon, L. Tsang et al., “Apelin concentrations are associated with altered atherosclerotic plaque stability mediator levels and atherosclerosis in rheumatoid arthritis,” Atherosclerosis, vol. 256, pp. 75–81, 2017. View at: Publisher Site | Google Scholar
  38. M. K. Akboga, A. Akyel, A. Sahinarslan et al., “Relationship between plasma apelin level and coronary collateral circulation,” Atherosclerosis, vol. 235, no. 2, pp. 289–294, 2014. View at: Publisher Site | Google Scholar
  39. L. Boutens, G. J. Hooiveld, S. Dhingra, R. A. Cramer, M. G. Netea, and R. Stienstra, “Unique metabolic activation of adipose tissue macrophages in obesity promotes inflammatory responses,” Diabetologia, vol. 61, no. 4, pp. 942–953, 2018. View at: Publisher Site | Google Scholar
  40. J. Beltowski, “Leptin and atherosclerosis,” Atherosclerosis, vol. 189, no. 1, pp. 47–60, 2006. View at: Publisher Site | Google Scholar
  41. K. K. Koh, S. M. Park, and M. J. Quon, “Leptin and cardiovascular disease: response to therapeutic interventions,” Circulation, vol. 117, no. 25, pp. 3238–3249, 2008. View at: Publisher Site | Google Scholar
  42. L. A. Vida Simiti, I. Todor, M. A. Stoia, C. M. Goidescu, F. P. Anton, and A. D. Farcaş, “Better prognosis in overweight/obese coronary heart disease patients with high plasma levels of leptin,” Clujul Medical, vol. 89, no. 1, pp. 65–71, 2016. View at: Publisher Site | Google Scholar
  43. J. Van de Voorde, B. Pauwels, C. Boydens, and K. Decaluwe, “Adipocytokines in relation to cardiovascular disease,” Metabolism, vol. 62, no. 11, pp. 1513–1521, 2013. View at: Publisher Site | Google Scholar
  44. D. Pop, D. Zdrenghea, L. Stanca, G. Bodisz, D. Petrovai, and B. Borz, “Adiponectin and leptin levels correlate with body mass index and lipid fractions but not with disturbances of glucose metabolism,” Acta Endocrinologica, vol. 5, no. 3, pp. 329–335, 2009. View at: Publisher Site | Google Scholar
  45. L. Liberale, F. Carbone, M. Bertolotto et al., “Serum adiponectin levels predict acute coronary syndrome (ACS) in patients with severe carotid stenosis,” Vascular Pharmacology, vol. 102, pp. 37–43, 2018. View at: Publisher Site | Google Scholar
  46. A. D. Farcaş, A. Rusu, M. A. Stoia, and L. A. Vida-Simiti, “Plasma leptin, but not resistin, TNF-α and adiponectin, is associated with echocardiographic parameters of cardiac remodeling in patients with coronary artery disease,” Cytokine, vol. 103, pp. 46–49, 2018. View at: Publisher Site | Google Scholar
  47. K. Selthofer-Relatić, R. Radić, A. Stupin et al., “Leptin/adiponectin ratio in overweight patients – gender differences,” Diabetes & Vascular Disease Research, vol. 15, no. 3, pp. 260–262, 2018. View at: Publisher Site | Google Scholar
  48. C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001. View at: Publisher Site | Google Scholar
  49. R. R. Banerjee, S. M. Rangwala, J. S. Shapiro et al., “Regulation of fasted blood glucose by resistin,” Science, vol. 303, no. 5661, pp. 1195–1198, 2004. View at: Publisher Site | Google Scholar
  50. D. B. Savage, C. P. Sewter, E. S. Klenk et al., “Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator–activated receptor-γ action in humans,” Diabetes, vol. 50, no. 10, pp. 2199–2202, 2001. View at: Publisher Site | Google Scholar
  51. L. Patel, A. C. Buckels, I. J. Kinghorn et al., “Resistin is expressed in human macrophages and directly regulated by PPARγ activators,” Biochemical and Biophysical Research Communications, vol. 300, no. 2, pp. 472–476, 2003. View at: Publisher Site | Google Scholar
  52. H. K. Park and R. S. Ahima, “Resistin in rodents and humans,” Diabetes & Metabolism Journal, vol. 37, no. 6, pp. 404–414, 2013. View at: Publisher Site | Google Scholar
  53. P. Codoner-Franch and E. Alonso-Iglesias, “Resistin: insulin resistance to malignancy,” Clinica Chimica Acta, vol. 438, pp. 46–54, 2015. View at: Publisher Site | Google Scholar
  54. H. Mu, R. Ohashi, S. Yan et al., “Adipokine resistin promotes in vitro angiogenesis of human endothelial cells,” Cardiovascular Research, vol. 70, no. 1, pp. 146–157, 2006. View at: Publisher Site | Google Scholar
  55. Y. H. Shen, L. Zhang, Y. Gan et al., “Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling. A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells,” The Journal of Biological Chemistry, vol. 281, no. 12, pp. 7727–7736, 2006. View at: Publisher Site | Google Scholar
  56. N. Leach, Ş. Vesa, E. Dronca, D. Sâmpelean, M. Lupşor, and M. Grigorescu, “Serum monocyte chemoattractant protein-1 levels and subclinical atherosclerosis in patients with non-alcoholic steatohepatitis,” Human and Veterinary Medicine, vol. 6, no. 2, pp. 76–82, 2014. View at: Google Scholar
  57. C. Chen, J. Jiang, J. M. Lü et al., “Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 299, no. 1, pp. H193–H201, 2010. View at: Publisher Site | Google Scholar
  58. Y. Cho, S. E. Lee, H. C. Lee et al., “Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery,” Journal of the American College of Cardiology, vol. 57, no. 1, pp. 99–109, 2011. View at: Publisher Site | Google Scholar
  59. M. Gerber, A. Boettner, B. Seidel et al., “Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 8, pp. 4503–4509, 2005. View at: Publisher Site | Google Scholar
  60. P. G. McTernan, F. M. Fisher, G. Valsamakis et al., “Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 12, pp. 6098–6106, 2003. View at: Publisher Site | Google Scholar
  61. G. D. Norata, M. Ongari, K. Garlaschelli, S. Raselli, L. Grigore, and A. L. Catapano, “Plasma resistin levels correlate with determinants of the metabolic syndrome,” European Journal of Endocrinology, vol. 156, no. 2, pp. 279–284, 2007. View at: Publisher Site | Google Scholar
  62. T. Pischon, C. M. Bamberger, J. Kratzsch et al., “Association of plasma resistin levels with coronary heart disease in women,” Obesity Research, vol. 13, no. 10, pp. 1764–1771, 2005. View at: Publisher Site | Google Scholar
  63. C. Weikert, S. Westphal, K. Berger et al., “Plasma resistin levels and risk of myocardial infarction and ischemic stroke,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 7, pp. 2647–2653, 2008. View at: Publisher Site | Google Scholar
  64. J. C. Engert, M. C. Vohl, S. M. Williams et al., “5 flanking variants of resistin are associated with obesity,” Diabetes, vol. 51, no. 5, pp. 1629–1634, 2002. View at: Publisher Site | Google Scholar
  65. H. Osawa, K. Yamada, H. Onuma et al., “The G/G genotype of a resistin single-nucleotide polymorphism at −420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3,” American Journal of Human Genetics, vol. 75, no. 4, pp. 678–686, 2004. View at: Publisher Site | Google Scholar
  66. O. Ukkola, A. Kunnari, and Y. A. Kesaniemi, “Genetic variants at the resistin locus are associated with the plasma resistin concentration and cardiovascular risk factors,” Regulatory Peptides, vol. 149, no. 1–3, pp. 56–59, 2008. View at: Publisher Site | Google Scholar
  67. C. H. Lau and S. Muniandy, “Adiponectin and resistin gene polymorphisms in association with their respective adipokine levels,” Annals of Human Genetics, vol. 75, no. 3, pp. 370–382, 2011. View at: Publisher Site | Google Scholar
  68. S. Kumar, V. Gupta, N. Srivastava et al., “Resistin 420C/G gene polymorphism on circulating resistin, metabolic risk factors and insulin resistance in adult women,” Immunology Letters, vol. 162, no. 2, pp. 287–291, 2014. View at: Publisher Site | Google Scholar
  69. A. Kunnari, O. Ukkola, and Y. A. Kesaniemi, “Resistin polymorphisms are associated with cerebrovascular disease in Finnish type 2 diabetic patients,” Diabetic Medicine, vol. 22, no. 5, pp. 583–589, 2005. View at: Publisher Site | Google Scholar
  70. O. Esbah, G. Gürsoy, N. G. Kirnap et al., “Relation of resistin levels with C-reactive protein, homocysteine and uric acid in smokers and non-smokers,” Journal of Research in Medical Sciences, vol. 16, no. 10, pp. 1273–1279, 2011. View at: Google Scholar
  71. E. Nakashima, A. Watarai, T. Tsukahara et al., “Association of resistin polymorphism, its serum levels and prevalence of stroke in Japanese type 2 diabetic patients,” Journal of Diabetes Investigation, vol. 1, no. 4, pp. 154–158, 2010. View at: Publisher Site | Google Scholar
  72. S. D. Bouziana, K. Tziomalos, A. Goulas, T.-A. Vyzantiadis, A. Panderi, and A. Ι. Hatzitolios, “Major adipokines and the −420C>G resistin gene polymorphism as predictors of acute ischemic stroke severity and in-hospital outcome,” Journal of Stroke and Cerebrovascular Diseases, vol. 27, no. 4, pp. 963–970, 2018. View at: Publisher Site | Google Scholar
  73. X. Y. Chen, J. H. Zhang, F. Liu, H. M. Liu, Y. Y. Song, and Y. L. Liu, “Association of serum resistin levels with metabolic syndrome and early atherosclerosis in obese Chinese children,” Journal of Pediatric Endocrinology & Metabolism, vol. 26, no. 9-10, pp. 855–860, 2013. View at: Publisher Site | Google Scholar
  74. É. Csongrádi, M. Káplár, B. Nagy Jr et al., “Adipokines as atherothrombotic risk factors in obese subjects: associations with haemostatic markers and common carotid wall thickness,” Nutrition, Metabolism, and Cardiovascular Diseases, vol. 27, no. 6, pp. 571–580, 2017. View at: Publisher Site | Google Scholar
  75. M. S. Burnett, C. W. Lee, T. D. Kinnaird et al., “The potential role of resistin in atherogenesis,” Atherosclerosis, vol. 182, no. 2, pp. 241–248, 2005. View at: Publisher Site | Google Scholar
  76. T. E. Korah, H. H. Ibrahim, E. A. E. Badr, and M. K. ElShafie, “Serum resistin in acute myocardial infarction patients with and without diabetes mellitus,” Postgraduate Medical Journal, vol. 87, no. 1029, pp. 463–467, 2011. View at: Publisher Site | Google Scholar
  77. E. Lubos, C. M. Messow, R. Schnabel et al., “Resistin, acute coronary syndrome and prognosis results from the AtheroGene study,” Atherosclerosis, vol. 193, no. 1, pp. 121–128, 2007. View at: Publisher Site | Google Scholar
  78. L. Li, J. L. Han, J. M. Mao, L. J. Guo, and W. Gao, “Association between serum resistin level and cardiovascular events in postmenopausal women with acute coronary syndrome undergoing percutaneous coronary intervention,” Chinese Medical Journal, vol. 126, no. 6, pp. 1058–1062, 2013. View at: Google Scholar
  79. H. B. Erer, N. Sayar, T. S. Guvenc et al., “Prognostic value of serum resistin levels in patients with acute myocardial infarction,” Kardiologia Polska, vol. 72, no. 2, pp. 181–186, 2014. View at: Publisher Site | Google Scholar
  80. G. Ntaios, N. K. Gatselis, K. Makaritsis, and G. N. Dalekos, “Adipokines as mediators of endothelial function and atherosclerosis,” Atherosclerosis, vol. 227, no. 2, pp. 216–221, 2013. View at: Publisher Site | Google Scholar
  81. A. Buturak, A. Değirmencioğlu, F. Bayrak et al., “Elective percutaneous coronary intervention leads to significant changes in serum resistin, leptin, and adiponectin levels regardless of periprocedural myocardial injury: an observational study,” The Anatolian Journal of Cardiology, vol. 16, no. 12, pp. 940–946, 2016. View at: Publisher Site | Google Scholar
  82. S. N. Rajpathak, R. C. Kaplan, S. Wassertheil-Smoller et al., “Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women’s Health Initiative,” Stroke, vol. 42, no. 7, pp. 1813–1820, 2011. View at: Publisher Site | Google Scholar
  83. B. J. Kim, S. H. Lee, W. S. Ryu, C. K. Kim, and B. W. Yoon, “Adipocytokines and ischemic stroke: differential associations between stroke subtypes,” Journal of the Neurological Sciences, vol. 312, no. 1-2, pp. 117–122, 2012. View at: Publisher Site | Google Scholar
  84. R. Krecki, M. Krzeminska-Pakula, J. Z. Peruga et al., “Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up,” Medical Science Monitor, vol. 17, no. 1, pp. CR26–CR32, 2011. View at: Publisher Site | Google Scholar
  85. S. P. Efstathiou, A. G. Tsiakou, D. I. Tsioulos et al., “Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke,” Clinica Chimica Acta, vol. 378, no. 1-2, pp. 78–85, 2007. View at: Publisher Site | Google Scholar
  86. L. Vida-Simiti, I. Todor, M. Stoia, C. Gherman, and C. Goidescu, “Plasma levels of resistin predict cardiovascular events,” Romanian Review of Laboratory Medicine, vol. 22, no. 1, pp. 35–47, 2014. View at: Publisher Site | Google Scholar
  87. C. D. Owens, J. M. Kim, N. D. Hevelone et al., “Novel adipokines, high molecular weight adiponectin and resistin, are associated with outcomes following lower extremity revascularization with autogenous vein,” Journal of Vascular Surgery, vol. 51, no. 5, pp. 1152–1159, 2010. View at: Publisher Site | Google Scholar

Copyright © 2018 Larisa-Diana Mocan Hognogi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.